Last reviewed · How we verify
LY3462817
At a glance
| Generic name | LY3462817 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (PHASE2)
- A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants (PHASE1)
- A Study of LY3462817 in Participants With Rheumatoid Arthritis (PHASE2)
- A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants (PHASE1)
- A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (PHASE1)
- A Safety Study of LY3462817 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3462817 CI brief — competitive landscape report
- LY3462817 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI